biostudies-literatureEhlers JPNEI NIH HHSNovartis Pharmaceuticals Corp1204-1213https://www.ebi.ac.uk/biostudies/studies/S-EPMC8387490biostudies-literatureUnknown5(12)<h4>Purpose</h4>To assess longitudinally the effect of anti-vascular endothelial growth factor (VEGF) treatment on ellipsoid zone (EZ) integrity, subretinal hyperreflective material (SHRM), and the sub-retinal pigment epithelium (sub-RPE) compartment in eyes with neovascular age-related macular degeneration (nAMD).<h4>Design</h4>Post hoc analysis of the OSPREY clinical trial, a prospective, double-masked, phase 2 study comparing brolucizumab 6 mg with aflibercept 2 mg over 56 weeks.<h4>Participants</h4>Participants with treatment-naïve nAMD at the initiation of the trial were included in the analysis.<h4>Methods</h4>Eyes were evaluated with spectral-domain OCT at 4-week intervals in the OSPREY trial (n = 81). Spectral-domain OCT scans collected from each visit were segmented automatically Ophthalmology. RetinaLongitudinal Assessment of Ellipsoid Zone Integrity, Subretinal Hyperreflective Material, and Subretinal Pigment Epithelium Disease in Neovascular Age-Related Macular Degeneration.PMC8387490K23 EY022947R34 EY029308Kaiser PKReese JLe TKSrivastava SKEhlers JPHu MHeier JSBrown DMMeng XLunasco LZahid RfalseLongitudinal Assessment of Ellipsoid Zone Integrity, Subretinal Hyperreflective Material, and Subretinal Pigment Epithelium Disease in Neovascular Age-Related Macular Degeneration.<h4>Purpose</h4>To assess longitudinally the effect of anti-vascular endothelial growth factor (VEGF) treatment on ellipsoid zone (EZ) integrity, subretinal hyperreflective material (SHRM), and the sub-retinal pigment epithelium (sub-RPE) compartment in eyes with neovascular age-related macular degeneration (nAMD).<h4>Design</h4>Post hoc analysis of the OSPREY clinical trial, a prospective, double-masked, phase 2 study comparing brolucizumab 6 mg with aflibercept 2 mg over 56 weeks.<h4>Participants</h4>Participants with treatment-naïve nAMD at the initiation of the trial were included in the analysis.<h4>Methods</h4>Eyes were evaluated with spectral-domain OCT at 4-week intervals in the OSPREY trial (n = 81). Spectral-domain OCT scans collected from each visit were segmented automatically 2021-01-01T00:00:00Z2021 Dec2025-04-19T15:40:02.729Z2025-04-19T15:40:02.729ZS-EPMC83874903364049310.1016/j.oret.2021.02.012